News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis Oncology (NVS): Afinitor(R) (everolimus) Now Licensed in UK for Advanced Kidney Cancer Patients After Failure of First Line Vascular Targeted Therapy(1, 2)


9/25/2009 11:07:39 AM

FRIMLEY, England, September 25 /PRNewswire/ -- Afinitor® (everolimus) has recently been licensed for the treatment of advanced kidney cancer after failure of treatments which prevent the growth of the tumour's blood vessels. The growth of the blood vessels are essential for the cancer to survive.(1) The European Commission (EC) approved everolimus for this use on 3rd August 2009.(1)

Read at PR Newswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES